Alnylam Pharmaceuticals ✓

@Alnylam · Cambridge, MA · joined 06 Aug 2009

Leader in #RNAiTherapeutics. Pioneer of this innovative approach to silencing the genes that cause disease. Community guidelines: https://t.co/AgfAVlmSG2.

17 468Followers

617Following

4 075Posts total

4.8KViews on collected posts

Последние посты

Alnylam Pharmaceuticals ✓@Alnylam23 Sep

⚽ Football and healthcare share something powerful: the ability to bring people together, inspire strength, and support communities. 💛🖤 In Germany, we are partnering with football club Borussia Dortmund (@BVB) women's team to raise awareness about acute hepatic porphyria https:

470 views · 5 likes · 0 reposts · 0 replies Open on X →

Alnylam Pharmaceuticals ✓@Alnylam22 Sep

Zilebesiran Program Lead, Simon Fox, shares his top 3 takeaways from our recent #RNAi Roundtable. Zilebesiran is an investigational RNAi therapeutic being evaluated in patients with high cardiovascular risk and uncontrolled #hypertension. Find out more here: https://t.co/iqFD0

1:21

579 views · 13 likes · 2 reposts · 0 replies Open on X →

Alnylam Pharmaceuticals ✓@Alnylam21 Sep

On World Alzheimer’s Day, we’re sharing this year’s message: The Earlier You Know, The More You Can Do. This message is important because early recognition is a significant step towards accessing information, support and care. At Alnylam, we stand with the dementia community in h

0:35

581 views · 4 likes · 0 reposts · 0 replies Open on X →

Alnylam Pharmaceuticals ✓@Alnylam17 Sep

Join us this morning for our 2nd RNAi Roundtable on our investigational #RNAi therapeutic zilebesiran. Learn about the challenges in hypertension management and the impact of prolonged uncontrolled blood pressure on cardiovascular risk. Join live or catch the replay later. 2.1K views · 12 likes · 2 reposts · 0 replies Open on X →

Alnylam Pharmaceuticals ✓@Alnylam14 Sep

Join us on Thursday for the second installment of our #RNAi Roundtable. Alnylam researchers and experts will discuss the significant unmet need in #hypertension, importance of blood pressure control, and ongoing research aimed at advancing cardiovascular care. 1K views · 10 likes · 2 reposts · 0 replies Open on X →

На фоне аккаунтов своего размера

5 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. обычный охват для своего размера, отклик слабее, чем у большинства.

Медианные просмотры581этот аккаунт924медиана для 10K–100K

Охват, %3.33%этот аккаунт3.62%медиана для 10K–100K

Вовлечённость, %1.06%этот аккаунт1.52%медиана для 10K–100K

Показатель	Этот аккаунт	Медиана для 10K–100K	Отношение
Медианные просмотры на пост	581	924	0.63×
Охват (просмотры ÷ подписчики)	3.33%	3.62%	0.92×
Вовлечённость	1.06%	1.52%	0.70×

Другие в этом диапазоне → Сравнить с другим аккаунтом → Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1K14 Sep

2.1K17 Sep

58121 Sep

57922 Sep

47023 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.17%14 Sep

0.76%17 Sep

0.69%21 Sep

2.59%22 Sep

1.06%23 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes80.0%44 in total

Reposts10.9%6 in total

Quotes3.6%2 in total

Bookmarks5.5%3 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.